Literature DB >> 10918185

Negative regulation of Fas-mediated apoptosis by FAP-1 in human cancer cells.

Y Li1, H Kanki, T Hachiya, T Ohyama, S Irie, G Tang, J Mukai, T Sato.   

Abstract

FAP-1 (Fas-associated phosphatase-1) was previously identified as a protein that associates with a negative regulatory domain (C-terminal 15 amino acids) of Fas using the yeast 2-hybrid system. Functional analysis indicated that FAP-1 expression correlates with resistance to Fas-induced apoptosis in human cancer cells. We first generated anti-FAP-1 polyclonal antibody and confirmed the interaction of FAP-1 and Fas in vivo. FAP-1 interacted with wild-type, but not mutant, Fas (tPLV) in 293T cells after transfecting FAP-1 and Fas or its mutant. To investigate the functional role of FAP-1 in Fas-mediated signal transduction, we established stable transfectants of FAP-1 in 3 human cancer cell lines. Apoptosis assays demonstrated that cancer cells over-expressing FAP-1 increased the resistance to Fas-induced apoptosis by the anti-Fas antibody CH-11 in contrast with the wild types or the vector-transfected cells. In addition, FAP-1 regulated the activity of both caspases 3 and 8. Our data indicate a functional role for FAP-1 as a negative regulator of Fas-mediated apoptosis in human cancer cells and suggest that an additional signal-transducing molecule may be required for complete suppression of Fas-mediated apoptosis. Copyright 2000 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10918185     DOI: 10.1002/1097-0215(20000815)87:4<473::aid-ijc3>3.0.co;2-1

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  13 in total

1.  miR-200c regulates induction of apoptosis through CD95 by targeting FAP-1.

Authors:  Robert Schickel; Sun-Mi Park; Andrea E Murmann; Marcus E Peter
Journal:  Mol Cell       Date:  2010-06-25       Impact factor: 17.970

2.  FAS Death Receptor: A Breast Cancer Subtype-Specific Radiation Response Biomarker and Potential Therapeutic Target.

Authors:  Janet K Horton; Sharareh Siamakpour-Reihani; Chen-Ting Lee; Ying Zhou; Wei Chen; Joseph Geradts; Diane R Fels; Peter Hoang; Kathleen A Ashcraft; Jeff Groth; Hsiu-Ni Kung; Mark W Dewhirst; Jen-Tsan A Chi
Journal:  Radiat Res       Date:  2015-10-21       Impact factor: 2.841

Review 3.  PTPN13/PTPL1: an important regulator of tumor aggressiveness.

Authors:  Gilles Freiss; Dany Chalbos
Journal:  Anticancer Agents Med Chem       Date:  2011-01       Impact factor: 2.505

4.  Expression and potential role of Fas-associated phosphatase-1 in ovarian cancer.

Authors:  I Meinhold-Heerlein; F Stenner-Liewen; H Liewen; S Kitada; M Krajewska; S Krajewski; J M Zapata; A Monks; D A Scudiero; T Bauknecht; J C Reed
Journal:  Am J Pathol       Date:  2001-04       Impact factor: 4.307

Review 5.  Molecular pathology of tumor metastasis III. Target array and combinatorial therapies.

Authors:  József Tímár; Andrea Ladányi; István Peták; András Jeney; László Kopper
Journal:  Pathol Oncol Res       Date:  2003-04-18       Impact factor: 3.201

6.  FAP-1 association with Fas (Apo-1) inhibits Fas expression on the cell surface.

Authors:  Vladimir N Ivanov; Pablo Lopez Bergami; Gabriel Maulit; Taka-Aki Sato; David Sassoon; Ze'ev Ronai
Journal:  Mol Cell Biol       Date:  2003-05       Impact factor: 4.272

7.  Pair-wise regulation of convergence and extension cell movements by four phosphatases via RhoA.

Authors:  Mark van Eekelen; Vincent Runtuwene; Wouter Masselink; Jeroen den Hertog
Journal:  PLoS One       Date:  2012-04-24       Impact factor: 3.240

8.  Indomethacin-induced activation of the death receptor-mediated apoptosis pathway circumvents acquired doxorubicin resistance in SCLC cells.

Authors:  D J A de Groot; T Timmer; D C J Spierings; T K P Le; S de Jong; E G E de Vries
Journal:  Br J Cancer       Date:  2005-04-25       Impact factor: 7.640

9.  Autophagy variation within a cell population determines cell fate through selective degradation of Fap-1.

Authors:  Jacob M Gump; Leah Staskiewicz; Michael J Morgan; Alison Bamberg; David W H Riches; Andrew Thorburn
Journal:  Nat Cell Biol       Date:  2013-12-08       Impact factor: 28.824

10.  Stat5 synergizes with T cell receptor/antigen stimulation in the development of lymphoblastic lymphoma.

Authors:  John A Kelly; Rosanne Spolski; Panu E Kovanen; Takeshi Suzuki; Julie Bollenbacher; Cynthia A Pise-Masison; Michael F Radonovich; Stephen Lee; Nancy A Jenkins; Neal G Copeland; Herbert C Morse; Warren J Leonard
Journal:  J Exp Med       Date:  2003-06-30       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.